Anne-Paule Gimenez-Roqueplo

List of Publications by Year
in descending order

182 papers	20,290 citations	13865 67 h-index	10732 138 g-index
192 all docs	192 docs citations	192 times ranked	13701 citing authors

#	Article	IF	Citations
1	Pheochromocytoma and Paraganglioma: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 1915-1942.	3.6	2,031
2	A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: the Lancet Commission on hypertension. Lancet, The, 2016, 388, 2665-2712.	13.7	670
3	Genetic Testing in Pheochromocytoma or Functional Paraganglioma. Journal of Clinical Oncology, 2005, 23, 8812-8818.	1.6	612
4	SDH Mutations Establish a Hypermethylator Phenotype in Paraganglioma. Cancer Cell, 2013, 23, 739-752.	16.8	606
5	SDHA is a tumor suppressor gene causing paraganglioma. Human Molecular Genetics, 2010, 19, 3011-3020.	2.9	604
6	Pheochromocytoma: recommendations for clinical practice from the First International Symposium. Nature Clinical Practice Endocrinology and Metabolism, 2007, 3, 92-102.	2.8	581
7	Clinical Presentation and Penetrance of Pheochromocytoma/Paraganglioma Syndromes. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 827-836.	3.6	560
8	Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma. Cancer Cell, 2017, 31, 181-193.	16.8	532
9	An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. Lancet Oncology, The, 2009, 10, 764-771.	10.7	477
10	Clinical and molecular genetics of patients with the Carneyâ€“Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD. European Journal of Human Genetics, 2008, 16, 79-88.	2.8	446
11	Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. Cancer Research, 2003, 63, 5615-21.	0.9	409
12	Succinate Dehydrogenase B Gene Mutations Predict Survival in Patients with Malignant Pheochromocytomas or Paragangliomas. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 3822-3828.	3.6	399
13	Paraganglioma and phaeochromocytoma: from genetics to personalized medicine. Nature Reviews Endocrinology, 2015, 11, 101-111.	9.6	396
14	The Succinate Dehydrogenase Genetic Testing in a Large Prospective Series of Patients with Paragangliomas. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 2817-2827.	3.6	353
15	European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma. European Journal of Endocrinology, 2016, 174, G1-G10.	3.7	352
16	The R22X Mutation of the SDHD Gene in Hereditary Paraganglioma Abolishes the Enzymatic Activity of Complex II in the Mitochondrial Respiratory Chain and Activates the Hypoxia Pathway. American Journal of Human Genetics, 2001, 69, 1186-1197.	6.2	339
17	Year of Diagnosis, Features at Presentation, and Risk of Recurrence in Patients with Pheochromocytoma or Secreting Paraganglioma. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 2110-2116.	3.6	324
18	Clinical Characteristics and Therapeutic Responses in Patients with Germ-LineAIPMutations and Pituitary Adenomas: An International Collaborative Study. Journal of Clinical Endocrinology and Metabolism, 2010, 95, E373-E383.	3.6	323

#	Article	IF	Citations
19	Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas. Human Molecular Genetics, 2014, 23, 2440-2446.	2.9	316
20	Aryl Hydrocarbon Receptor-Interacting Protein Gene Mutations in Familial Isolated Pituitary Adenomas: Analysis in 73 Families. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 1891-1896.	3.6	283
21	MAX Mutations Cause Hereditary and Sporadic Pheochromocytoma and Paraganglioma. Clinical Cancer Research, 2012, 18, 2828-2837.	7.0	277
22	An Update on the Genetics of Paraganglioma, Pheochromocytoma, and Associated Hereditary Syndromes. Hormone and Metabolic Research, 2012, 44, 328-333.	1.5	269
23	Haplotypes of Angiotensinogen in Essential Hypertension. American Journal of Human Genetics, 1997, 60, 1448-1460.	6.2	267
24	Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma. Human Molecular Genetics, 2011, 20, 3974-3985.	2.9	266
25	SDHA Immunohistochemistry Detects Germline SDHA Gene Mutations in Apparently Sporadic Paragangliomas and Pheochromocytomas. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E1472-E1476.	3.6	257
26	Fibromuscular dysplasia. Orphanet Journal of Rare Diseases, 2007, 2, 28.	2.7	245
27	Functional Consequences of aSDHBGene Mutation in an Apparently Sporadic Pheochromocytoma. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 4771-4774.	3.6	210
28	The Warburg Effect Is Genetically Determined in Inherited Pheochromocytomas. PLoS ONE, 2009, 4, e7094.	2.5	203
29	Consensus Statement on next-generation-sequencing-based diagnostic testing of hereditary phaeochromocytomas and paragangliomas. Nature Reviews Endocrinology, 2017, 13, 233-247.	9.6	198
30	Spectrum of Mutations in Gitelman Syndrome. Journal of the American Society of Nephrology: JASN, 2011, 22, 693-703.	6.1	190
31	Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. Journal of Hypertension, 2020, 38, 1443-1456.	0.5	190
32	SDHB/SDHA immunohistochemistry in pheochromocytomas and paragangliomas: a multicenter interobserver variation analysis using virtual microscopy: a Multinational Study of the European Network for the Study of Adrenal Tumors (ENS@T). Modern Pathology, 2015, 28, 807-821.	5.5	176
33	Metastatic Pheochromocytoma/Paraganglioma Related to Primary Tumor Development in Childhood or Adolescence: Significant Link to SDHB Mutations. Journal of Clinical Oncology, 2011, 29, 4137-4142.	1.6	170
34	Loss of succinate dehydrogenase activity results in dependency on pyruvate carboxylation for cellular anabolism. Nature Communications, 2015, 6, 8784.	12.8	169
35	Spectrum of hemojuvelin gene mutations in 1q-linked juvenile hemochromatosis. Blood, 2004, 103, 4317-4321.	1.4	167
36	SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma. International Journal of Cancer, 2014, 135, 2711-2720.	5.1	155

#	Article	IF	Citations
37	Multi-omics analysis defines core genomic alterations in pheochromocytomas and paragangliomas. Nature Communications, 2015, 6, 6044.	12.8	153
38	Mitochondrial succinate is instrumental for HIF1Î± nuclear translocation in SDHA-mutant fibroblasts under normoxic conditions. Human Molecular Genetics, 2005, 14, 3263-3269.	2.9	146
39	PHACTR1 Is a Genetic Susceptibility Locus for Fibromuscular Dysplasia Supporting Its Complex Genetic Pattern of Inheritance. PLoS Genetics, 2016, 12, e1006367.	3.5	146
40	Phaeochromocytoma, new genes and screening strategies. Clinical Endocrinology, 2006, 65, 699-705.	2.4	130
41	Imaging Work-Up for Screening of Paraganglioma and Pheochromocytoma inSDHxMutation Carriers: A Multicenter Prospective Study from the PGL.EVA Investigators. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E162-E173.	3.6	130
42	Seven Lessons From Two Candidate Genes in Human Essential Hypertension. Hypertension, 1999, 33, 1324-1331.	2.7	129
43	Germline inactivating mutations of the aryl hydrocarbon receptor-interacting protein gene in a large cohort of sporadic acromegaly: mutations are found in a subset of young patients with macroadenomas. European Journal of Endocrinology, 2007, 157, 1-8.	3.7	127
44	Somatic NF1 inactivation is a frequent event in sporadic pheochromocytoma. Human Molecular Genetics, 2012, 21, 5397-5405.	2.9	126
45	Genetics of Pheochromocytoma and Paraganglioma in Spanish Patients. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 1701-1705.	3.6	120
46	Oncometabolitesâ€driven tumorigenesis: From genetics to targeted therapy. International Journal of Cancer, 2014, 135, 2237-2248.	5.1	119
47	Clinical aspects of SDHx-related pheochromocytoma and paraganglioma. Endocrine-Related Cancer, 2009, 16, 391-400.	3.1	117
48	Isocitrate Dehydrogenase Mutations Are Rare in Pheochromocytomas and Paragangliomas. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 1274-1278.	3.6	116
49	Head and Neck Paragangliomas in Von Hippel-Lindau Disease and Multiple Endocrine Neoplasia Type 2. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 1938-1944.	3.6	112
50	An overview of 20Âyears of genetic studies in pheochromocytoma and paraganglioma. Best Practice and Research in Clinical Endocrinology and Metabolism, 2020, 34, 101416.	4.7	106
51	A Decade (2001-2010) of Genetic Testing for Pheochromocytoma and Paraganglioma. Hormone and Metabolic Research, 2012, 44, 359-366.	1.5	103
52	Reassessing the clinical spectrum associated with hereditary leiomyomatosis and renal cell carcinoma syndrome in French <scp>FH</scp> mutation carriers. Clinical Genetics, 2017, 92, 606-615.	2.0	103
53	Prognosis of Malignant Pheochromocytoma and Paraganglioma (MAPP-Prono Study): A European Network for the Study of Adrenal Tumors Retrospective Study. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 2367-2374.	3.6	103
54	One-Year Progression-Free Survival of Therapy-Naive Patients With Malignant Pheochromocytoma and Paraganglioma. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 4006-4012.	3.6	102

#	Article	IF	Citations
55	Genetic Basis of Congenital Erythrocytosis: Mutation Update and Online Databases. Human Mutation, 2014, 35, 15-26.	2.5	101
56	Inheritance of arterial lesions in renal fibromuscular dysplasia. Journal of Human Hypertension, 2007, 21, 393-400.	2.2	99
57	Inactivation of theAPCGene Is Constant in Adrenocortical Tumors from Patients with Familial Adenomatous Polyposis but Not Frequent in Sporadic Adrenocortical Cancers. Clinical Cancer Research, 2010, 16, 5133-5141.	7.0	97
58	Germline Mutations in the Mitochondrial 2-Oxoglutarate/Malate Carrier SLC25A11 Gene Confer a Predisposition to Metastatic Paragangliomas. Cancer Research, 2018, 78, 1914-1922.	0.9	96
59	Tricarboxylic acid cycle dysfunction as a cause of human diseases and tumor formation. American Journal of Physiology - Cell Physiology, 2006, 291, C1114-C1120.	4.6	95
60	Pheochromocytomas: The (pseudo)-hypoxia hypothesis. Best Practice and Research in Clinical Endocrinology and Metabolism, 2010, 24, 957-968.	4.7	94
61	Epithelial to Mesenchymal Transition Is Activated in Metastatic Pheochromocytomas and Paragangliomas Caused by SDHB Gene Mutations. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E954-E962.	3.6	87
62	Mosaicism inHIF2A-Related Polycythemia-Paraganglioma Syndrome. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E369-E373.	3.6	87
63	Positive Impact of Genetic Test on the Management and Outcome of Patients With Paraganglioma and/or Pheochromocytoma. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 1109-1118.	3.6	82
64	Telomerase Activation and ATRX Mutations Are Independent Risk Factors for Metastatic Pheochromocytoma and Paraganglioma. Clinical Cancer Research, 2019, 25, 760-770.	7.0	82
65	International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers. Nature Reviews Endocrinology, 2021, 17, 435-444.	9.6	80
66	Pheochromocytomas and secreting paragangliomas. Orphanet Journal of Rare Diseases, 2006, 1, 49.	2.7	75
67	Rationale for Anti-angiogenic Therapy in Pheochromocytoma and Paraganglioma. Endocrine Pathology, 2012, 23, 34-42.	9.0	75
68	Identification of a new VHL exon and complex splicing alterations in familial erythrocytosis or von Hippel-Lindau disease. Blood, 2018, 132, 469-483.	1.4	70
69	Long-term Postoperative Follow-up in Patients with Apparently Benign Pheochromocytoma and Paraganglioma. Hormone and Metabolic Research, 2012, 44, 385-389.	1.5	66
70	Unsuspected task for an old team: Succinate, fumarate and other Krebs cycle acids in metabolic remodeling. Biochimica Et Biophysica Acta - Bioenergetics, 2014, 1837, 1330-1337.	1.0	66
71	Identification of Potential Gene Markers and Insights into the Pathophysiology of Pheochromocytoma Malignancy. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 4865-4872.	3.6	61
72	Targeted next-generation sequencing detects rare genetic events in pheochromocytoma and paraganglioma. Journal of Medical Genetics, 2019, 56, 513-520.	3.2	60

#	Article	IF	Citations
73	HIF2AMutations in Paraganglioma with Polycythemia. New England Journal of Medicine, 2012, 367, 2161-2162.	27.0	59
74	Hereditary Paraganglioma/Pheochromocytoma and Inherited Succinate Dehydrogenase Deficiency. Hormone Research in Paediatrics, 2005, 63, 171-179.	1.8	57
75	TMEM127Screening in a Large Cohort of Patients with Pheochromocytoma and/or Paraganglioma. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E805-E809.	3.6	57
76	RECENT ADVANCES IN THE GENETICS OF PHAEOCHROMOCYTOMA AND FUNCTIONAL PARAGANGLIOMA. Clinical and Experimental Pharmacology and Physiology, 2008, 35, 376-379.	1.9	55
77	Penetrance and clinical consequences of a gross SDHB deletion in a large family. Clinical Genetics, 2009, 75, 354-363.	2.0	54
78	In Vivo Detection of Succinate by Magnetic Resonance Spectroscopy as a Hallmark of SDHx Mutations in Paraganglioma. Clinical Cancer Research, 2016, 22, 1120-1129.	7.0	54
79	Integrative multi-omics analysis identifies a prognostic miRNA signature and a targetable miR-21-3p/TSC2/mTOR axis in metastatic pheochromocytoma/paraganglioma. Theranostics, 2019, 9, 4946-4958.	10.0	54
80	DNA Methylation Profiling in Pheochromocytoma and Paraganglioma Reveals Diagnostic and Prognostic Markers. Clinical Cancer Research, 2015, 21, 3020-3030.	7.0	53
81	Deciphering the molecular basis of invasiveness in Sdhb-deficient cells. Oncotarget, 2015, 6, 32955-32965.	1.8	52
82	Angiotensinogen variants and human hypertension. Current Hypertension Reports, 1999, 1, 31-41.	3.5	50
83	Distinct deregulation of the hypoxia inducible factor by PHD2 mutants identified in germline DNA of patients with polycythemia. Haematologica, 2012, 97, 9-14.	3.5	50
84	Rethinking pheochromocytomas and paragangliomas from a genomic perspective. Oncogene, 2016, 35, 1080-1089.	5.9	50
85	TET-Mediated Hypermethylation Primes SDH-Deficient Cells for HIF2Î±-Driven Mesenchymal Transition. Cell Reports, 2020, 30, 4551-4566.e7.	6.4	49
86	Malignant head/neck paragangliomas. Comparative Study. European Annals of Otorhinolaryngology, Head and Neck Diseases, 2014, 131, 159-166.	0.7	47
87	A novel TMEM127 mutation in a patient with familial bilateral pheochromocytoma. European Journal of Endocrinology, 2011, 164, 141-145.	3.7	46
88	SDHD Immunohistochemistry: A New Tool to ValidateSDHxMutations in Pheochromocytoma/Paraganglioma. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E287-E291.	3.6	45
89	Role of MDH2 pathogenic variant in pheochromocytoma and paraganglioma patients. Genetics in Medicine, 2018, 20, 1652-1662.	2.4	45
90	Evidence for carotid and radial artery wall subclinical lesions in renal fibromuscular dysplasia. Journal of Hypertension, 2003, 21, 2287-2295.	0.5	44

#	Article	IF	Citations
91	Initial work-up and long-term follow-up in patients with phaeochromocytomas and paragangliomas. Best Practice and Research in Clinical Endocrinology and Metabolism, 2006, 20, 421-434.	4.7	44
92	Mutations associated with succinate dehydrogenase <scp>d</scp>â€related malignant paragangliomas. Clinical Endocrinology, 2008, 68, 561-566.	2.4	44
93	Guidelines for reporting secondary findings of genome sequencing in cancer genes: the SFMPP recommendations. European Journal of Human Genetics, 2018, 26, 1732-1742.	2.8	44
94	Evolutionarily conserved susceptibility of the mitochondrial respiratory chain to SDHI pesticides and its consequence on the impact of SDHIs on human cultured cells. PLoS ONE, 2019, 14, e0224132.	2.5	43
95	Pheochromocytoma and paraganglioma. Current Opinion in Oncology, 2016, 28, 5-10.	2.4	40
96	A thyroid nodule revealing a paraganglioma in a patient with a new germline mutation in the succinate dehydrogenase B gene. European Journal of Endocrinology, 2004, 151, 433-438.	3.7	39
97	A germline mutation inPBRM1predisposes to renal cell carcinoma. Journal of Medical Genetics, 2015, 52, 426-430.	3.2	38
98	Risk assessment of maternally inheritedSDHDparaganglioma and phaeochromocytoma. Journal of Medical Genetics, 2017, 54, 125-133.	3.2	37
99	Role of N-Glycosylation in Human Angiotensinogen. Journal of Biological Chemistry, 1998, 273, 21232-21238.	3.4	36
100	The genetics of paragangliomas. European Annals of Otorhinolaryngology, Head and Neck Diseases, 2012, 129, 315-318.	0.7	34
101	From Nf1 to Sdhb knockout: Successes and failures in the quest for animal models of pheochromocytoma. Molecular and Cellular Endocrinology, 2016, 421, 40-48.	3.2	34
102	Risk Profile of the RET A883F Germline Mutation: An International Collaborative Study. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 2069-2074.	3.6	34
103	Sino-European Differences in the Genetic Landscape and Clinical Presentation of Pheochromocytoma and Paraganglioma. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 3295-3307.	3.6	34
104	Peritoneal Implantation of Pheochromocytoma Following Tumor Capsule Rupture During Surgery. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E2681-E2685.	3.6	33
105	Low-grade oncocytic renal tumor (LOT): mutations in mTOR pathway genes and low expression of FOXI1. Modern Pathology, 2022, 35, 352-360.	5.5	33
106	HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: Metastatic pheochromocytomas and paragangliomas: proceedings of the MEN2019 workshop. Endocrine-Related Cancer, 2020, 27, T41-T52.	3.1	33
107	Relative Expression of the RET9 and RET51 Isoforms in Human Pheochromocytomas. Oncology, 2000, 58, 311-318.	1.9	32
108	Genetic Evidence of a Precisely Tuned Dysregulation in the Hypoxia Signaling Pathway during Oncogenesis. Cancer Research, 2014, 74, 6554-6564.	0.9	32

#	Article	IF	Citations
109	Nationwide French Study of RET Variants Detected from 2003 to 2013 Suggests a Possible Influence of Polymorphisms as Modifiers. Thyroid, 2017, 27, 1511-1522.	4.5	32
110	Carbonic anhydrase 9 immunohistochemistry as a tool to predict or validate germline and somatic VHL mutations in pheochromocytoma and paragangliomaâ€"a retrospective and prospective study. Modern Pathology, 2020, 33, 57-64.	5.5	30
111	Î±1-antitrypsin gene polymorphisms are not associated with renal arterial fibromuscular dysplasia. Journal of Hypertension, 2006, 24, 705-710.	0.5	29
112	Genetic Testing in Pheochromocytoma: Increasing Importance for Clinical Decision Making. Annals of the New York Academy of Sciences, 2006, 1073, 94-103.	3.8	29
113	A SDHC Founder Mutation Causes Paragangliomas (PGLs) in the French Canadians: New Insights on the SDHC-Related PGL. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 4710-4718.	3.6	28
114	The value of a rapid contrast-enhanced angio-MRI protocol in the detection of head and neck paragangliomas in SDHx mutations carriers: a retrospective study on behalf of the PGL.EVA investigators*. European Radiology, 2016, 26, 1696-1704.	4.5	28
115	Changes in Urinary Total Metanephrine Excretion in Recurrent and Malignant Pheochromocytomas and Secreting Paragangliomas. Annals of the New York Academy of Sciences, 2006, 1073, 383-391.	3.8	26
116	Rapid determination of tricarboxylic acid cycle enzyme activities in biological samples. BMC Biochemistry, 2010, 11, 5.	4.4	26
117	Loss of SDHB Promotes Dysregulated Iron Homeostasis, Oxidative Stress, and Sensitivity to Ascorbate. Cancer Research, 2021, 81, 3480-3494.	0.9	26
118	Juvenile hemochromatosis HJV-related revealed by cardiogenic shock. Blood Cells, Molecules, and Diseases, 2004, 33, 120-124.	1.4	25
119	Functional and in silico assessment of MAX variants of unknown significance. Journal of Molecular Medicine, 2015, 93, 1247-1255.	3.9	25
120	The genetic basis of pheochromocytoma: who to screen and how?. Nature Clinical Practice Endocrinology and Metabolism, 2006, 2, 60-61.	2.8	23
121	Screening in asymptomatic SDHx mutation carriers: added value of 18F-FDG PET/CT at initial diagnosis and 1-year follow-up. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 868-876.	6.4	23
122	Development of Novel Tools for the Diagnosis and Prognosis of Pheochromocytoma Using Peptide Marker Immunoassay and Gene Expression Profiling Approaches. Annals of the New York Academy of Sciences, 2006, 1073, 533-540.	3.8	22
123	Succinate detection using in vivo 1H-MR spectroscopy identifies germline and somatic SDHx mutations in paragangliomas. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1510-1517.	6.4	22
124	Role of Cysteine Residues in Human Angiotensinogen. Journal of Biological Chemistry, 1998, 273, 34480-34487.	3.4	21
125	Mitochondrial Deficiencies in the Predisposition to Paraganglioma. Metabolites, 2017, 7, 17.	2.9	21
126	Pheochromocytoma and Paraganglioma in Children and Adolescents: Experience of the French Society of Pediatric Oncology (SFCE). Journal of the Endocrine Society, 2020, 4, bvaa039.	0.2	21

#	Article	IF	Citations
127	Characterization of a Human Angiotensinogen Cleaved in Its Reactive Center Loop by a Proteolytic Activity from Chinese Hamster Ovary Cells. Journal of Biological Chemistry, 2000, 275, 10648-10654.	3.4	20
128	Evaluation of a Standardized Protocol for Processing Adrenal Tumor Samples: Preparation for a European Adrenal Tumor Bank. Hormone and Metabolic Research, 2010, 42, 93-101.	1.5	20
129	New Advances in the Genetics of Pheochromocytoma and Paraganglioma Syndromes. Annals of the New York Academy of Sciences, 2006, 1073, 112-121.	3.8	19
130	Vemurafenib and cobimetinib overcome resistance to vemurafenib in BRAF -mutant ganglioglioma. Neurology, 2018, 91, 523-525.	1.1	19
131	Targeted Metabolomics as a Tool in Discriminating Endocrine From Primary Hypertension. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e1111-e1128.	3.6	19
132	Presymptomatic Genetic Testing in Minors at Risk of Paraganglioma and Pheochromocytoma: Our Experience of Oncogenetic Multidisciplinary Consultation. Hormone and Metabolic Research, 2012, 44, 354-358.	1.5	17
133	Immunohistochemical expression of stem cell markers in pheochromocytomas/paragangliomas is associated with SDHx mutations. European Journal of Endocrinology, 2015, 173, 43-52.	3.7	17
134	Glucocorticoid Excess in Patients with Pheochromocytoma Compared with Paraganglioma and Other Forms of Hypertension. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3374-e3383.	3.6	17
135	Primary hyperparathyroidism as first manifestation in multiple endocrine neoplasia type 2A: an international multicenter study. Endocrine Connections, 2020, 9, 489-497.	1.9	17
136	The Natural Mutation Y248C of Human Angiotensinogen Leads to Abnormal Glycosylation and Altered Immunological Recognition of the Protein. Journal of Biological Chemistry, 1996, 271, 9838-9844.	3.4	16
137	Vascular Endothelial Growth Factor-A Is Associated with Chronic Mountain Sickness in the Andean Population. High Altitude Medicine and Biology, 2014, 15, 146-154.	0.9	16
138	The MITF, p.E318K Variant, as a Risk Factor for Pheochromocytoma and Paraganglioma. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 4764-4768.	3.6	16
139	MET alterations in biphasic squamoid alveolar papillary renal cell carcinomas and clinicopathological features. Modern Pathology, 2021, 34, 647-659.	5.5	16
140	Pheochromocytoma and Paraganglioma: Progress on all Fronts. Endocrine Pathology, 2012, 23, 1-3.	9.0	15
141	Emerging molecular markers of metastatic pheochromocytomas and paragangliomas. Annales D'Endocrinologie, 2019, 80, 159-162.	1.4	15
142	Oncogenic features of the bone morphogenic protein 7 (BMP7) in pheochromocytoma. Oncotarget, 2015, 6, 39111-39126.	1.8	15
143	Vascular Pattern Analysis for the Prediction of Clinical Behaviour in Pheochromocytomas and Paragangliomas. PLoS ONE, 2015, 10, e0121361.	2.5	14
144	Usefulness of FDG-PET/CT-Based Radiomics for the Characterization and Genetic Orientation of Pheochromocytomas Before Surgery. Cancers, 2020, 12, 2424.	3.7	13

#	Article	IF	Citations
145	A role for succinate dehydrogenase genes in low chemoresponsiveness to hypoxia?. Clinical Autonomic Research, 2009, 19, 335-342.	2.5	12
146	Germline mutations in the new E1â€™ cryptic exon of the VHL gene in patients with tumours of von Hippel-Lindau disease spectrum or with paraganglioma. Journal of Medical Genetics, 2020, 57, 752-759.	3.2	12
147	Transcriptome Analysis of lncRNAs in Pheochromocytomas and Paragangliomas. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 898-907.	3.6	11
148	p.Ala541Thr variant of MEN1 gene: A non deleterious polymorphism or a pathogenic mutation?. Annales D'Endocrinologie, 2014, 75, 133-140.	1.4	10
149	The mTORC1 Complex Is Significantly Overactivated in <i>SDHX</i>-Mutated Paragangliomas. Neuroendocrinology, 2017, 105, 384-393.	2.5	10
150	Pheochromocytoma: When to search a germline defect?. Presse Medicale, 2018, 47, e109-e118.	1.9	10
151	Screening of a Large Cohort of Asymptomatic SDHx Mutation Carriers in Routine Practice. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e1301-e1315.	3.6	10
152	Identity by Descent Mapping of Founder Mutations in Cancer Using High-Resolution Tumor SNP Data. PLoS ONE, 2012, 7, e35897.	2.5	8
153	Functional Characterization of TMEM127 Variants Reveals Novel Insights into Its Membrane Topology and Trafficking. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3142-e3156.	3.6	8
154	Genotype-Phenotype Features of Germline Variants of the TMEM127 Pheochromocytoma Susceptibility Gene: A 10-Year Update. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e350-e364.	3.6	8
155	Recurrence-Free Survival Analysis in Locally Advanced Pheochromocytoma: First Appraisal. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 2726-2737.	3.6	8
156	Stent treatment for pseudocoarctation and refractory hypertension in an elderly patient with Takayasu's arteritis. Nephrology Dialysis Transplantation, 2000, 15, 536-538.	0.7	7
157	Successful Targeting of an ATG7-RAF1 Gene Fusion in Anaplastic Pleomorphic Xanthoastrocytoma With Leptomeningeal Dissemination. JCO Precision Oncology, 2019, 3, 1-7.	3.0	7
158	Germline DLST Variants Promote Epigenetic Modifications in Pheochromocytoma-Paraganglioma. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 459-471.	3.6	6
159	Expression of LHCGR in Pheochromocytomas Unveils an Endocrine Mechanism Connecting Pregnancy and Epinephrine Overproduction. Hypertension, 2022, 79, 1006-1016.	2.7	6
160	International initiative for a curated SDHB variant database improving the diagnosis of hereditary paraganglioma and pheochromocytoma. Journal of Medical Genetics, 2022, 59, 785-792.	3.2	5
161	Quantifying evidence toward pathogenicity for rare phenotypes: The case of succinate dehydrogenase genes, SDHB and SDHD. Genetics in Medicine, 2022, 24, 41-50.	2.4	5
162	Overexpression of miRâ€483â€5p is confined to metastases and linked to high circulating levels in patients with metastatic pheochromocytoma/paraganglioma. Clinical and Translational Medicine, 2020, 10, e260.	4.0	4

#	Article	IF	Citations
163	Adrenal tumors: when to search for a germline abnormality?. Current Opinion in Oncology, 2019, 31, 230-235.	2.4	3
164	Successful response to pegylated interferon alpha in a patient with recurrent paraganglioma. Endocrine-Related Cancer, 2017, 24, L7-L11.	3.1	2
165	Perioperative outcomes of pheochromocytoma/paraganglioma surgery preceded by Takotsubo-like cardiomyopathy. Surgery, 2022, 172, 913-918.	1.9	2
166	THE SDHB AND VHL GENES SHOULD BE SYSTEMATICALLY TESTED IN PATIENTS WITH NONSYNDROMIC PHEOCHROMOCYTOMA. Journal of Hypertension, 2004, 22, S210-S211.	0.5	1
167	Abstract 4371: Integrated molecular characterization of pheochromocytoma and paraganglioma including a novel, recurrent and prognostic fusion gene. Cancer Research, 2016, 76, 4371-4371.	0.9	1
168	Apports de COMETE Ã la gÃ©nÃ©tique du phÃ©ochromocytome. Bulletin De L'Academie Nationale De Medecine, 2008, 192, 105-116.	0.0	1
169	Parler Ã lâ€™enfant du risque de maladie gÃ©nÃ©tique. Corps Et Psychisme, 2020, NÂ° 75, 79-92.	0.0	1
170	Inheritance of arterial lesions in renal fibromuscular dysplasia. Journal of Hypertension, 2007, 25, A3.	0.5	0
171	Detection of large rearrangements in the pheochromocytomas genes using QMPSF (quantitative) Tj ETQq1 1 0.784314 rgBT /Overloc Hypertension, 2007, 25, A2.	0.5	0
172	Genetics of chromaffin tumors. Expert Review of Endocrinology and Metabolism, 2009, 4, 143-151.	2.4	0
173	[OP.3A.06] LONG TERM FOLLOW-UP IN PATIENTS OPERATED ON A PHEOCHROMOCYTOMA OR A PARAGANGLIOMA. Journal of Hypertension, 2016, 34, e28.	0.5	0
174	⁶⁸Ga-DOTATATE PET/CT Versus MRI: Why the Comparison of ⁶⁸Ga-DOTATATE PET/CT to an Appropriate MRI Protocol Is Essential. Journal of Nuclear Medicine, 2017, 58, 184-185.	5.0	0
175	Pheochromocytoma/Paraganglioma: Management, Genetics, and Follow-up. , 2019, , 469-477.		0
176	FEATURES AT PRESENTATION AND RISK OF RECURRENCE IN PATIENTS WITH PHEOCHROMOCYTOMA. Journal of Hypertension, 2004, 22, S186.	0.5	0
177	RESULTS OF THE FRENCH PARAGANGLIOMA RESEARCH NETWORK (PGL.NET). Journal of Hypertension, 2004, 22, S145.	0.5	0
178	THE HIF-PATHWAY, NEW CANDIDATE GENES FOR PARAGANGLIOMA AND/OR PHEOCHROMOCYTOMA?. Journal of Hypertension, 2004, 22, S77.	0.5	0
179	Le rÃ©seau national COMETE sur les tumeurs de la surrÃ©nale. Bulletin De L'Academie Nationale De Medecine, 2008, 192, 73-85.	0.0	0
180	Characterization of Stem Cell Markers in Pheochromocytomas and Paragangliomas. Experimental and Clinical Endocrinology and Diabetes, 2014, 122, .	1.2	0

#	Article	IF	Citations
181	Paraganglioma, Malignant. Encyclopedia of Earth Sciences Series, 2016, , 337-340.	0.1	0
182	Genetic spectrum in a Canadian cohort of apparently sporadic pheochromocytomas and paragangliomas: New data on multigene panel retesting over time. Clinical Endocrinology, 2021, , .	2.4	0